title: Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
abstract: OBJECTIVE
  To retrospectively investigate the short-term therapeutic effects and adverse effects associated with the use of miriplatin-lipiodol suspension for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), using TACE with cisplatin-lipiodol suspension as the historical control.
  
  
  METHODS
  The study was conducted on 48 and 50 consecutive patients with HCC who underwent TACE with miriplatin-lipiodol suspension and cisplatin-lipiodol suspension, respectively. Therapeutic effect was evaluated by mRECIST. Adverse effects were graded by CTCAE, version 4.0. The therapeutic and adverse effects were compared using Fisher's exact test and multivariate logistic regression.
  
  
  RESULTS
  Complete remission, partial response, stable disease and progressive disease were observed in 37.5, 18.8, 33.3 and 10.4 % of patients in the miriplatin group, with the corresponding percentages being 54.0, 32.0, 14.0 and 0.0 %, respectively, in the cisplatin group. The short-term therapeutic effects were statistically significantly worse in the miriplatin group than in the cisplatin group, even after adjustment for tumor size and Child-Pugh class. The rates of nausea and serum creatinine elevation were statistically significantly lower in the miriplatin group (p < 0.05).
  
  
  CONCLUSIONS
  TACE using miriplatin-lipiodol suspension yielded worse short-term responses than cisplatin-lipiodol suspension; however, the rates of adverse events were significantly lower in the miriplatin group.
authors.affiliation: Department of Diagnostic Radiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. soguro@rad.med.keio.ac.jp
authors.forename: Sota
authors.initials: S
authors.lastname: Oguro
authors.forename: Subaru
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Tomoki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Masanori
authors.initials: M
authors.lastname: Inoue
authors.forename: Seishi
authors.initials: S
authors.lastname: Nakatsuka
authors.forename: Sachio
authors.initials: S
authors.lastname: Kuribayashi
authors.forename: Keiko
authors.initials: K
authors.lastname: Asakura
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Kawachi
authors.forename: Minoru
authors.initials: M
authors.lastname: Tanabe
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Ebinuma
authors.forename: Hidetsugu
authors.initials: H
authors.lastname: Saito
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Hibi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D002404:Catheterization; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage; D004998:Ethiodized Oil / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D013535:Suspensions; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D013535:Suspensions; C406530:miriplatin; D004998:Ethiodized Oil; D002945:Cisplatin